The biotherapeutics pipeline is increasingly diversifying, as antibody variants such as bispecifics, conjugates, and fragments move through preclinical stages to commercial manufacturing. Many of these variants, especially asymmetric bispecific antibodies, are prone to aggregation or to forming product-related impurities such as homodimers and half-antibodies during cell culture. The similarities between these impurities present extra challenges in the downstream process, especially post-capture. One potential solution is to initiate polishing at the capture step using differences in avidity.<br/>Here we present data on applications using an alkaline-tolerant, high-capacity capture resin with novel selectivity to purify challenging entities.

Purifying challenging entities: Using differences in avidity to polish during the capture step

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.